Pharmaceutical manufacturer and marketer
Products are prescription and OTC (over the counter) drugs. Main focus is on sales and marketing and as they do not develop early stage new products, new product growth is by acquisition. Products are sold in more than 150 countries, with own sales companies in 60 countries. Product areas are respiratory, dermatological and pain/inflammation. Acquired by Mylan in 2016.
| Mylan NV
owns 100% of Meda AB
This company is listed as having worst practice on a report card on lesbian, gay, bisexual and transgender equality in corporate America.
[Source 2014][More on Workers Rights]
This company received a score of 20.2/100 in the Newsweek Green Rankings 2016, which ranks the world's largest publicly traded companies on eight indicators covering energy, greenhouse gases, water, waste, fines and penalties, linking executive pay to sustainability targets, board-level committee oversight of environmental issues and third-party audits. Ranking methodology by Corporate Knights and HIP Investor.
[Source 2016][More on Sustainability Reporting]
Mylan, the makers of the EpiPen, an injectable device that is filled with medicine and can stop a life-threatening allergic reaction with immediate effect, have increased the price of the device from $100 in 2008 to above $500 in 2016, making it a hike of over 400 per cent. Epipens only cost a few dollars to make and the price-hike has caused a public outcry.
[Source 2016][More on Governance]
OpenSecrets.org tracks the influence of money on U.S. politics, and how that money affects policy and citizens' lives. Follow link to see this company's record of political donations, lobbying, outside spending and more.
|Company Structure||Wholly-owned subsidiary|
|Revenue||US$2.3 billion in 2015|
|# Employees||4,600 in 2015|
|Subsidiaries||Meda Pharmaceuticals Pty Ltd|
Products / BrandsMeda Australia
Waxsol Eye & Ear Care